Infliximab for managing steroid-refractory acute graft-versus-host disease.

  title={Infliximab for managing steroid-refractory acute graft-versus-host disease.},
  author={Joseph A Pidala and Jongphil Kim and Teresa L. Field and Ali McBride and Mohamed A Kharfan-Dabaja and Janelle B Perkins and Hugo F Fernandez and Lia Elena Perez and Ernesto Ayala and Claudio Anasetti},
  journal={Biology of blood and marrow transplantation : journal of the American Society for Blood and Marrow Transplantation},
  volume={15 9},
Infliximab has demonstrated activity in the treatment of steroid-refractory acute graft-versus-host disease (aGVHD). We aimed to confirm the effectiveness of infliximab as a salvage therapy for steroid-refractory aGVHD. In a series of 52 patients, 71% of whom had grade III-IV aGVHD, only 15% achieved complete remission (CR) with the use of infliximab alone as salvage therapy. CR of aGVHD differed according to overall aGVHD grade at salvage (grade II, 5/15; grade III, 2/17; grade IV, 1/20; P=.03… CONTINUE READING


Publications citing this paper.
Showing 1-10 of 10 extracted citations


Publications referenced by this paper.
Showing 1-10 of 46 references

Similar Papers

Loading similar papers…